DK2569333T3 - Nye muterede humaniserede 12g4-antistoffer og fragmenter deraf rettet mod den humane type ii-receptor for anti-müllersk hormon - Google Patents
Nye muterede humaniserede 12g4-antistoffer og fragmenter deraf rettet mod den humane type ii-receptor for anti-müllersk hormon Download PDFInfo
- Publication number
- DK2569333T3 DK2569333T3 DK11718450.7T DK11718450T DK2569333T3 DK 2569333 T3 DK2569333 T3 DK 2569333T3 DK 11718450 T DK11718450 T DK 11718450T DK 2569333 T3 DK2569333 T3 DK 2569333T3
- Authority
- DK
- Denmark
- Prior art keywords
- ser
- val
- thr
- gly
- lys
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57449—Specifically defined cancers of ovaries
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/72—Assays involving receptors, cell surface antigens or cell surface determinants for hormones
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Endocrinology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Inorganic Chemistry (AREA)
- Neurology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Analytical Chemistry (AREA)
- Reproductive Health (AREA)
Claims (10)
1. Muteret humaniseret monoklonalt 12G4-antistof, der specifikt binder til type 11-receptoren for humant anti-mullersk hormon, hvilket antistof har: a) en let kæde bestående af aminosyresekvensen, der er repræsenteret af: - SEQ ID NO: 82 eller SEQ ID NO: 84 og b) en tung kæde bestående af aminosyresekvensen, der er repræsenteret af: - SEQ ID NO: 86 eller SEQ ID NO: 88.
2. Nukleinsyre, der omfatter eller er udgjort af en sekvens, som koder for antistoffet ifølge krav 1.
3. Nukleinsyre ifølge krav 2, i hvilken sekvensen, der koder for den lette kæde, og sekvensen, der koder for den tunge kæde, er som følger: a) sekvens, der koder for den lette kæde SEQ ID NO: 81 eller SEQ ID NO: 83 og b) sekvens, der koder for den tunge kæde SEQ ID NO: 85 eller SEQ ID NO: 87.
4. Ekspressionsvektor, der omfatter mindst en nukleinsyre ifølge et hvilket som helst af kravene 2 og 3, hvor nukleinsyren er under kontrol af elementerne, der muliggør dens ekspression, og omfatter: • en første nukleinsyre med sekvensen SEQ ID NO 83, hvor den første nukleinsyre er under kontrol af elementerne, der muliggør dens ekspression, og • en anden nukleinsyre med sekvensen SEQ ID NO 87, hvor den anden nukleinsyre er under kontrol af elementerne, der muliggør dens ekspression.
5. Værtscelle eller cellelinje, der er transformeret med en nukleinsyre ifølge et af kravene 2 og 3 og/eller en ekspressionsvektor ifølge krav 4.
6. Farmaceutisk sammensætning, og navnlig vaccinationssammensætning, der omfatter mindst • et monoklonalt antistof ifølge krav 1, eller • en nukleinsyre ifølge et hvilket som helst af kravene 2 og 3, eller • en vektor ifølge krav 4, i kombination med et farmaceutisk acceptabelt bærestof.
7. Produkt, der omfatter et første farmaceutisk præparat, som omfatter et monoklonalt antistof ifølge krav 1, og et andet farmaceutisk præparat, som omfatter en traditionel cancerbekæmpende forbindelse, navnlig paclitaxel eller et platinsalt, især oxaloplatin, cisplatin eller carboplatin, i sin egenskab af kombinationspræparat til samtidig, adskilt eller sekventiel anvendelse ved behandling af patienter, der lider af ovariecancer.
8. Monoklonalt antistof ifølge krav 1, eller nukleinsyre ifølge et hvilket som helst af kravene 2 og 3, eller vektor ifølge krav 4, eller celle ifølge krav 5, til anvendelse ved behandling eller forebyggelse af ovariecancer, især hvor det monoklonale antistof eller nukleinsyren eller vektoren eller cellen anvendes i kombination med et traditionelt cancerbekæmpende middel, navnlig paclitaxel eller et platinsalt, især oxaloplatin, cisplatin eller carboplatin.
9. Monoklonalt antistof ifølge krav 1 til anvendelse ved diagnostik og/eller overvågning af ovariecancer, der er forbundet med type Il-receptoren for humant anti-mullersk hormon.
10. Fremgangsmåde til diagnostik af ovariecancer, der er forbundet med type Il-receptoren for humant anti-mullersk hormon, på en human biologisk prøve, hvilken fremgangsmåde omfatter følgende trin: a. mærkning af en biopsi, der forinden er udtaget fra en patient, ved hjælp af et monoklonalt antistof ifølge krav 1 b. bestemmelse af tilstedeværelsen af en type Il-receptor for humant anti-miillersk hormon.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR1053712A FR2959994B1 (fr) | 2010-05-12 | 2010-05-12 | Nouveaux anticorps humanises 12g4 mutes et leurs fragments diriges contre le recepteur humain de l'hormone anti-mullerienne de type ii |
PCT/FR2011/050745 WO2011141653A1 (fr) | 2010-05-12 | 2011-04-01 | Nouveaux anticorps humanises 12g4 mutes et leurs fragments diriges contre le recepteur humain de l'hormone anti-mullerienne de type ii |
Publications (1)
Publication Number | Publication Date |
---|---|
DK2569333T3 true DK2569333T3 (da) | 2018-03-26 |
Family
ID=43413855
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK11718450.7T DK2569333T3 (da) | 2010-05-12 | 2011-04-01 | Nye muterede humaniserede 12g4-antistoffer og fragmenter deraf rettet mod den humane type ii-receptor for anti-müllersk hormon |
Country Status (11)
Country | Link |
---|---|
US (2) | US9012607B2 (da) |
EP (1) | EP2569333B1 (da) |
JP (2) | JP6043998B2 (da) |
CN (1) | CN103119059B (da) |
AR (1) | AR081159A1 (da) |
BR (1) | BR112012028859B1 (da) |
CA (1) | CA2798336C (da) |
DK (1) | DK2569333T3 (da) |
ES (1) | ES2661080T3 (da) |
FR (1) | FR2959994B1 (da) |
WO (1) | WO2011141653A1 (da) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2737457B1 (en) | 2011-07-26 | 2019-11-20 | United Parcel Service Of America, Inc. | Systems and methods for managing fault codes |
FR2984750B1 (fr) | 2011-12-23 | 2014-01-10 | Lfb Biotechnologies | Nouvelles compositions pharmaceutiques comprenant un anticorps liant le recepteur humain de l'hormone anti-mullerienne de type ii |
EP3331569A1 (en) * | 2015-08-07 | 2018-06-13 | Gamamabs Pharma | Antibodies, antibody drug conjugates and methods of use |
WO2017079303A1 (en) * | 2015-11-02 | 2017-05-11 | The Cleveland Clinic Foundation | Sequentially orchestrated immune checkpoint therapy for the treatment and prevention of cancer |
FR3060394B1 (fr) * | 2016-12-16 | 2019-05-24 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies | Combinaison d'anticorps anti-cd303 et anti-amhrii |
KR20200014277A (ko) * | 2017-04-14 | 2020-02-10 | 가마맵스 파마 | 폐암을 예방 또는 치료하기 위한 amhrii-결합 화합물 |
CN110891970B (zh) * | 2017-04-14 | 2024-05-10 | 埃克塞里艾克西斯公司 | 用于预防或治疗癌症的amhrii结合化合物 |
CN111108123A (zh) * | 2017-05-29 | 2020-05-05 | 加马玛布斯制药公司 | 癌症相关的免疫抑制抑制剂 |
EP3789401A1 (en) | 2019-09-03 | 2021-03-10 | Gamamabs Pharma | Amhrii-binding antibody drug conjugates and their use thereof in the treatment of cancers |
EP3812008A1 (en) | 2019-10-23 | 2021-04-28 | Gamamabs Pharma | Amh-competitive antagonist antibody |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002049672A2 (en) * | 2000-12-21 | 2002-06-27 | Mcgill University | Conjugates of antibodies and anticancer drugs |
AR039067A1 (es) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
US7217797B2 (en) * | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
WO2005005615A2 (en) * | 2003-07-08 | 2005-01-20 | Fox Chase Cancer Center | Anti-mullerian inhibiting substance type ii receptor (misiir) immunoconjugates to detect and treat cancer |
US8957187B2 (en) * | 2005-12-02 | 2015-02-17 | Genentech, Inc. | Binding polypeptides and uses thereof |
EP2010226B1 (en) * | 2006-04-07 | 2014-01-15 | The Research Foundation of State University of New York | Transcobalamin receptor polypeptides, nucleic acids, and modulators thereof, and related methods of use in modulating cell growth and treating cancer and cobalamin deficiency |
CN101506358B (zh) * | 2006-05-15 | 2013-07-17 | 免疫医学股份有限公司 | 使用偶合的抗体或抗体片段治疗人免疫缺陷病毒感染的方法和组合物 |
EP1918304A1 (en) * | 2006-11-02 | 2008-05-07 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Monoclonal antibodies against the human anti-müllerian hormone type II receptor (AMHR-II) |
-
2010
- 2010-05-12 FR FR1053712A patent/FR2959994B1/fr active Active
-
2011
- 2011-04-01 EP EP11718450.7A patent/EP2569333B1/fr active Active
- 2011-04-01 CN CN201180032211.8A patent/CN103119059B/zh active Active
- 2011-04-01 US US13/697,575 patent/US9012607B2/en active Active
- 2011-04-01 AR ARP110101115A patent/AR081159A1/es active IP Right Grant
- 2011-04-01 BR BR112012028859-8A patent/BR112012028859B1/pt active IP Right Grant
- 2011-04-01 CA CA2798336A patent/CA2798336C/fr active Active
- 2011-04-01 DK DK11718450.7T patent/DK2569333T3/da active
- 2011-04-01 ES ES11718450.7T patent/ES2661080T3/es active Active
- 2011-04-01 WO PCT/FR2011/050745 patent/WO2011141653A1/fr active Application Filing
- 2011-04-01 JP JP2013509591A patent/JP6043998B2/ja active Active
-
2015
- 2015-03-16 US US14/658,785 patent/US9637544B2/en active Active
-
2016
- 2016-07-26 JP JP2016146495A patent/JP6435295B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP6043998B2 (ja) | 2016-12-14 |
EP2569333B1 (fr) | 2017-12-13 |
US20150232563A1 (en) | 2015-08-20 |
ES2661080T3 (es) | 2018-03-27 |
FR2959994B1 (fr) | 2012-08-24 |
CN103119059B (zh) | 2016-06-29 |
WO2011141653A1 (fr) | 2011-11-17 |
BR112012028859B1 (pt) | 2022-02-22 |
FR2959994A1 (fr) | 2011-11-18 |
BR112012028859A8 (pt) | 2017-12-05 |
JP6435295B2 (ja) | 2018-12-05 |
CA2798336C (fr) | 2018-08-21 |
JP2017029139A (ja) | 2017-02-09 |
JP2013534408A (ja) | 2013-09-05 |
US20130136743A1 (en) | 2013-05-30 |
US9637544B2 (en) | 2017-05-02 |
AR081159A1 (es) | 2012-07-04 |
CA2798336A1 (fr) | 2011-11-17 |
EP2569333A1 (fr) | 2013-03-20 |
BR112012028859A2 (da) | 2017-08-15 |
US9012607B2 (en) | 2015-04-21 |
CN103119059A (zh) | 2013-05-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK2569333T3 (da) | Nye muterede humaniserede 12g4-antistoffer og fragmenter deraf rettet mod den humane type ii-receptor for anti-müllersk hormon | |
US9982055B2 (en) | Antibody against the CSF-1R | |
WO2021063336A1 (zh) | 靶向cldn18.2的抗体及其制备方法和应用 | |
CN113227146B (zh) | 密蛋白18.2结合部分和其用途 | |
JP6895890B2 (ja) | ヒト化抗muc1* 抗体 | |
EP2132229B1 (en) | Recombinant anti-epidermal growth factor receptor antibody compositions | |
EP2262836B1 (en) | Antibody against the csf-1 r | |
JP7282401B2 (ja) | 癌治療のための抗fam19a5抗体の用途 | |
JP2019516394A (ja) | 新規抗pd−l1抗体 | |
JP7360441B2 (ja) | メソテリン及びcd137結合分子 | |
EP3820908A1 (en) | Anti-mesothelin antibodies | |
CN113754780A (zh) | 靶向cldn18.2的嵌合抗原受体、其组合物及用途 | |
KR20230158058A (ko) | 시알산-결합 ig-유사 렉틴 15에 특이적인 항체 및 이의 용도 | |
TW202208438A (zh) | 抗lilrb1抗體或其抗原結合片段、製備其的方法、藥物組成物、核酸分子、重組載體以及重組細胞 | |
KR20220048028A (ko) | 항-cd19 항체 및 그의 용도 | |
TW202043271A (zh) | 重組抗人程序性細胞死亡蛋白1抗體及其應用 | |
KR20240026496A (ko) | 항-넥틴4 항체 및 이를 포함하는 다중특이적 단백질 복합체 |